Literature DB >> 11278797

Proteolytic activation of ETK/Bmx tyrosine kinase by caspases.

Y M Wu1, C L Huang, H J Kung, C Y Huang.   

Abstract

Etk/Bmx is a member of the Btk/Tec family of kinases, which are characterized by having a pleckstrin homology domain at the N terminus, in addition to the Src homology 3 (SH3), SH2, and the catalytic domains, shared with the Src family kinases. Etk, or Btk kinases in general, has been implicated in the regulation of apoptosis. To test whether Etk is the substrate for caspases during apoptosis, in vitro translated [(35)S]methionine-labeled Etk was incubated with different apoptotic extracts and recombinant caspases, respectively. Results showed that Etk was proteolyzed in all conditions tested with identical cleavage patterns. Caspase-mediated cleavage of Etk generated a C-terminal fragment, containing the complete SH2 and tyrosine kinase domains, but without intact pleckstrin homology and SH3 domains. This fragment has 4-fold higher kinase activity than that of the full-length Etk. Ectopic expression of the C-terminal fragment of Etk sensitized the PC3 prostate cancer cells to apoptosis in response to apoptosis-inducing stimuli. The finding, together with an earlier report that Etk is potentially antiapoptotic, suggests that Etk may serve as an apoptotic switch, depending on the forms of Etk existing inside the cells. To our knowledge, this is the first case where the activity of a tyrosine kinase is induced by caspase cleavage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278797     DOI: 10.1074/jbc.M010964200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

Review 1.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

Review 2.  The N-end rule pathway and regulation by proteolysis.

Authors:  Alexander Varshavsky
Journal:  Protein Sci       Date:  2011-08       Impact factor: 6.725

3.  Augmented generation of protein fragments during wakefulness as the molecular cause of sleep: a hypothesis.

Authors:  Alexander Varshavsky
Journal:  Protein Sci       Date:  2012-11       Impact factor: 6.725

4.  Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.

Authors:  Olga A Guryanova; Qiulian Wu; Lin Cheng; Justin D Lathia; Zhi Huang; Jinbo Yang; Jennifer MacSwords; Christine E Eyler; Roger E McLendon; John M Heddleston; Weinian Shou; Dolores Hambardzumyan; Jeongwu Lee; Anita B Hjelmeland; Andrew E Sloan; Markus Bredel; George R Stark; Jeremy N Rich; Shideng Bao
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

5.  Phosphorylation Impacts N-end Rule Degradation of the Proteolytically Activated Form of BMX Kinase.

Authors:  Mohamed A Eldeeb; Richard P Fahlman
Journal:  J Biol Chem       Date:  2016-09-06       Impact factor: 5.157

6.  Loss of Bmx nonreceptor tyrosine kinase prevents pressure overload-induced cardiac hypertrophy.

Authors:  Scherise A Mitchell-Jordan; Tanja Holopainen; Shuxun Ren; Sujing Wang; Sarah Warburton; Michael J Zhang; Kari Alitalo; Yibin Wang; Thomas M Vondriska
Journal:  Circ Res       Date:  2008-11-06       Impact factor: 17.367

Review 7.  Targeting tyrosine kinases and autophagy in prostate cancer.

Authors:  Hsing-Jien Kung
Journal:  Horm Cancer       Date:  2010-12-02       Impact factor: 3.869

8.  A multi-factor model for caspase degradome prediction.

Authors:  Lawrence J K Wee; Joo Chuan Tong; Tin Wee Tan; Shoba Ranganathan
Journal:  BMC Genomics       Date:  2009-12-03       Impact factor: 3.969

9.  Caspase-dependent cleavage of c-Abl contributes to apoptosis.

Authors:  Daniela Barilà; Alessandra Rufini; Ivano Condò; Natascia Ventura; Karel Dorey; Giulio Superti-Furga; Roberto Testi
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

10.  CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors.

Authors:  Wenchang Guo; Ruiwu Liu; Gaurav Bhardwaj; Ai-Hong Ma; Chun Changou; Joy C Yang; Yuanpei Li; Caihong Feng; Yan Luo; Anisha Mazloom; Eduardo Sanchez; Yan Wang; Wenzhe Huang; Randen Patterson; Christopher P Evans; Kit S Lam; Hsing-Jien Kung
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.